NDAINTRAVENOUSPOWDER
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
(HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylated histones,…
Indications (1)
Clinical Trials (5)
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Started Feb 2021
50 enrolled
PTCL
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Started Feb 2020
0Lymphoma, T-Cell
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Started Feb 2019
150 enrolled
Lymphoma, T-Cell, Peripheral
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Started Sep 2018
11 enrolled
Lymphoma, T-Cell, Peripheral
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Started Dec 2017
23 enrolled
Cutaneous T-cell LymphomaT-Prolymphocytic LeukemiaT-Large Granulocytic Leukemia+2 more